Relationship between the regulatory region polymorphism of human tissue kallikrein gene and essential hypertension

Journal of Human Hypertension

Volumn 19, Issue 9, 2005, Pages 715-721

  Hua, H ^a   Zhou, S ^a   Liu, Y ^a   Wang, Zhengrong ^a   Wan, C ^b   Li, H ^a   Chen, C ^c   Li, G ^d   Zeng, C ^e   Chen, L ^f   Chao, L ^g   Chao, J ^g  

^a SICHUAN UNIVERSITY   (China)

^b WEST CHINA UNIVERSITY OF MEDICAL SCIENCES   (China)

^c Department of Internal Medicine   (China)

^d Central Hospital of Nanchong   (China)

^e The 7th Hospital of Chengdu   (China)

^f The People Hospital of Suining   (China)

^g MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Polymerase chain reaction; Polymorphism; Population; Tissue kallikrein

Indexed keywords

KALLIKREIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA POLYMORPHISM; ESSENTIAL HYPERTENSION; FEMALE; FREQUENCY ANALYSIS; GENE FREQUENCY; GENE IDENTIFICATION; GENE LOCUS; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC CODE; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; OLIGONUCLEOTIDE PROBE; POLYMERASE CHAIN REACTION; REGULATORY MECHANISM; RISK ASSESSMENT; STUDENT T TEST;

ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; REGULATORY SEQUENCES, NUCLEIC ACID; TISSUE KALLIKREINS;

EID: 31044439840     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1001875     Document Type: Article

References (26)

1. Meneton P et al. Cardiovascular abnormalities with normal blood pressure in tissue kallikrein deficient mice. Proc Natl Acad Sci USA 2001; 98: 2634-2639.
2. Campbell DJ. The kallikrein-kinin system in humans. Clin Exp Pharmacol Physiol 2001; 28(12): 1060-1065.
3. Linz W et al. Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. Pharmacol Rev 1995; 47: 25-49.
4. Siragy HM, Jaffa AA, Margolius HS, Carey RM. Renin-angiotensin system modulates renal bradykinin production. Am J Physiol 1996; 271: R1090-R1095.
5. Harvey TJ et al. Tissue-specific expression patterns and fine mapping of the human kallikrein (KLK) locus on proximal 19q13.4. J Biol Chem 2000; 275: 37397-37406.
6. Evans BA et al. Structure and chromosomal localization of the human renal kallikrein gene. Biochemistry 1988; 27: 3124-3129.
7. Lifton RP. Molecular genetics of human blood pressure variation. Science 1996; 272: 676-680.
8. Pravence M et al. Cosegregation of blood pressure with a kallikrein gene family polymorphism. Hypertension 1991; 17: 242-246.
9. Wang J et al. Human tissue kallikrein induces hypotension in transgenic mice. Hypertension 1994; 23: 236-243.
10. Berry TD et al. A gene for high urinary kallikrein may protect against hypertension in Utah kindreds. Hypertension 1989; 13: 3-8.
11. Berge KE, Berg K. A Taq I RFLP at the human renal kallikrein (KLK1) locus. Clin Genet 1991; 40: 256.
12. Berge KE, Berg K. No effect of Taq I polymorphism at the human renal kallikrein (KLK1) locus on normal blood pressure level or variability. Clin Genet 1993; 44: 196-202.
13. Richards RI et al. Human glandular kallikrein genes genetic and physical mapping of the KLK1 locus using a highly polymorphic microsatellite PCR marker. Genomics 1991; 11: 77-82.
14. Song Q, Chao J, Chao L. DNA polymorphisms in the 5′-flanking region of the human tissue kallikrein gene. Hum Genet 1997; 99: 727-734.
15. Slim R et al. Loss-of-function polymorphism of the human kallikrein gene with reduced urinary kallikrein activity. J Am Soc Nephrol 2002; 13: 968-976.
16. Lifton RP, Gharavi AG, Geller DS. Molecular mechanisms of human hypertension. Cell 2001; 104: 545-556.
17. Staessen JA, Wang J, Bianchi G, Birkenhager WH. Essential hypertension. Lancet 2003; 361: 1629-1641.
18. Clements JA. The glandular kallikrein family of enzyme: Tissue specific expression and hormonal regulation. Endocr Rev 1989; 10: 393-419.
19. Bhoola KD, Figueroa CD, Worthy K. Bioregulation of kinins: Kallikreins, kininogens, and kininases. Pharmacol Rev 1992; 44: 1-80.
20. Margolius HS. Tissue kallikreins and kinins: Regulation and roles in hypertensive and diabetic diseases. Ann Rev Pharmacol Toxicol 1989; 29: 343-364.
21. Overlack A. Antihypertensive effect of orally administered glandular kallikrein in essential hypertension. Results of double blind study. Hypertension 1981; 3: 118-121.
22. Ogawa KT. Effects of orally administered glandular kallikrein on urinary kallikrein and prostaglandin excretion, plasma immunoreactive prostanoids and platelet aggregation in essential hypertension. Klin Wochenschr 1985; 63: 332-336.
23. Xiong W, Chao J, Chao L. Muscle delivery of human tissue kallikrein gene reduces blood pressure in spontaneously hypertensive rats. Hypertension 1995; 25: 715-719.
24. Harrap SB. Where are all the blood-pressure genes? Lancet 2003; 361: 2149-2151.
25. Margolius HS, Horwitz D, Pisano JJ, Keiser HR. Urinary kallikrein in hypertension: Relationship to sodium intake and sodium-retaining steroid. Circ Res 1974; 35: 820-825.
26. Cotton RG. Current methods of mutation detection. Mutat Res 1993; 285: 125-144.